Favorable outcome after physiologic dose of sodium-D,L-3-hydroxybutyrate in severe MADD.

Van Rijt, Willemijn J; Heiner-Fokkema, M Rebecca; du Marchie Sarvaas, Gideon J; Waterham, Hans R; Blokpoel, Robert G T; van Spronsen, Francjan J; Derks, Terry G J · Pediatrics · 2014

case_report · Level V

Where this comes from

Abstract

Multiple acyl coenzyme A dehydrogenase deficiency (MADD) is a severe inborn error of metabolism. Experiences with sodium-D,L-3-hydroxybutyrate (3-HB) treatment are limited although positive; however, the general view on outcome of severely affected patients with MADD is relatively pessimistic. Here we present an infant with MADD in whom the previously reported dose of 3-HB did not prevent the acute, severe, metabolic decompensation or progressive cardiomyopathy in the subsequent months. Only after a physiologic dose of 2600 mg/kg of 3-HB per day were ketone bodies detected in blood associated with improvement of the clinical course, N-terminal prohormone of brain natriuretic peptide and echocardiographic parameters. Long-term studies are warranted on 3-HB treatment in patients with MADD.

Medical subject headings